Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 10/20 | 0.38 |
| ▸ | MAOA | P21397 | 3/20 | 0.37 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23717119 | 0.86 | NAMPT (0.36) | NAMPT | |
| SCHEMBL23683753 | 0.84 | ALDH1A1 (0.40) | NAMPT | |
| SCHEMBL23717393 | 0.83 | NAMPT (0.36) | NAMPTMAOAMAOB | |
| SCHEMBL23717091 | 0.83 | NAMPT (0.36) | NAMPTMAOAMAOB | |
| SCHEMBL24986252 | 0.80 | NAMPT (0.36) | NAMPTMAOAMAOB | |
| SCHEMBL24986254 | 0.80 | NAMPT (0.36) | NAMPTMAOAMAOB | |
| SCHEMBL23685117 | 0.80 | CSNK1D (0.34) | — | |
| SCHEMBL23717087 | 0.80 | SLC5A7 (0.32) | MAOAMAOB | |
| SCHEMBL23685145 | 0.80 | CFTR (0.32) | — | |
| SCHEMBL24345444 | 0.80 | CSNK1D (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | VIP, ACE, FURIN | NAMPT 224/4885MAOA 2105/4885MAOB 1788/4885 |
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | VIP, ACE, FURIN | NAMPT 224/4885MAOA 2105/4885MAOB 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.